Funding for this research was provided by:
Karolinska Institute
Article History
Accepted: 29 May 2023
First Online: 8 July 2023
Declarations
:
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work, and have given final approval to the version to be published. All authors contributed to the conceptualization of the study, data curation, investigation, reviewing and editing of the manuscript. NJ and LJ contributed to the formal analyses, and project administration. LJ designed the methodology and model. NJ wrote the original draft. LJ and NW contributed to the supervision and validation of findings.
: No funding was received to conduct this study.
: The datasets generated and/or analysed during this study were obtained from the Swedish National Quality Register for Breast Cancer (NKBC) and eHälsomyndigheten. Summary data from the former can be found here: . Patient-level data from the former and product-specific sales data from the latter are only available upon application and approval of the study-specific request.
: Analyses of the individual-patient level data were performed in R, the models were built in Excel
: The study was approved by the Swedish Ethical Review Authority (Etikprövningsmyndigheten) Dnr 2021-06709-01 and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
: Nahila Justo is employed by Evidera, which provides consulting and other research services to pharmaceutical, medical devices, and related organisations. In her salaried position, she works with a variety of companies and organisations, and is precluded from receiving payment or honoraria directly from these organisations for services rendered. The work herein was not conducted as part of her employment. Nils Wilking reports personal fees from AstraZeneca, Bayer, Daichii Sankyo, Incyte, Jansen, MSD, Novartis, Pierre Fabre and Oasmia for participation in advisory boards and educational activities. Linus Jönsson has no competing interests to declare.
: Not applicable
: Not applicable